Company Overview
Akanda Corp. operates within the Healthcare sector, specifically functioning in the Drug Manufacturers - Specialty & Generic industry, where it engages in the cultivation, manufacture, and distribution of cannabis-based products. As a publicly traded entity with the ticker symbol AKAN, the company was incorporated in 2021 and has since expanded its operations through subsidiaries to serve the specialized pharmaceutical and cannabinoid markets. The firm currently holds a market capitalization of $1.43M and reports trailing twelve-month revenue of $836,664, while its employee count is listed as N/A in available records. These valuation and revenue figures indicate that Akanda Corp. functions as a micro-cap entity with a very small market presence, suggesting a niche operational scale rather than broad market dominance. The combination of a sub-$2M market cap and revenue under $1M places the company in a category where financial stability is heavily dependent on specific product line performance and successful execution in the competitive cannabis landscape.
Financial Health
The company reports trailing twelve-month revenue of $836,664, yet it simultaneously posts a net income of $-2,395,394 and an EBITDA of $-3,678,018, highlighting a significant divergence between top-line sales and bottom-line profitability. This substantial gap between revenue and net income reveals a cost structure where operating expenses far exceed gross profits, resulting in a net loss that is more than three times the size of the annual revenue. Furthermore, the free cash flow stands at $-4,874,154, which indicates a severe lack of financial flexibility and an inability to generate cash from operations to fund internal growth or debt servicing without external capital injections. The gross margin is recorded at 24.9%, suggesting that the company retains nearly a quarter of its revenue as direct profit before overhead costs, yet the operating margin plunges to -443.8%, signaling that general and administrative expenses are disproportionately high relative to sales volume. Additionally, the profit margin of -266.3% confirms that the company is losing money on every dollar of revenue generated, a common characteristic in early-stage biotech or specialty drug firms but critical for investors to monitor. On the balance sheet, total cash holdings of $2.52M provide some liquidity buffer against total debt of $391,241, though the debt-to-equity ratio of 11.85 indicates a highly leveraged position relative to shareholder equity. The current ratio of 1.25 suggests the company maintains a conservative short-term liquidity stance, possessing assets slightly higher than its current liabilities, which offers a minimal safety net against immediate obligations. Finally, the return on equity of -60.9% and return on assets of -28.7% reveal that management effectiveness is currently negative, as the company is destroying shareholder value and utilizing assets inefficiently to generate profit.
Valuation Assessment
The trailing P/E ratio is listed as 0.00 due to the negative earnings, while the forward P/E is N/A, implying that analysts or the market currently cannot project a normalized earnings trajectory to support a standard multiple-based valuation. The price-to-book ratio of 0.03 indicates that the stock trades at a negligible fraction of its book value, suggesting the market prices the company well below the net asset value recorded on its balance sheet. The price-to-sales ratio of 1.71 and the EV/EBITDA of 0.56 offer alternative valuation perspectives, suggesting the market values the company based on a significant portion of its sales rather than earnings power, which is typical for loss-making entities. The 52-week high is $46.45 and the 52-week low is $0.55, placing the current valuation context within a massive volatility range where the stock price has fluctuated more than 8,000% from its lowest point to its highest point. Although the exact current price is not explicitly stated as a single figure in the provided facts, the proximity of the low to the current trading environment suggests the stock is trading near the bottom of its historical range relative to the 52-week high. The beta of 1.69 indicates that the stock exhibits high volatility relative to the broader market, moving with 69% greater amplitude than the market index, which increases risk for conservative investors seeking stable returns.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, preventing a direct comparison of whether earnings are growing faster or slower than revenue at this specific point in time. Since the dividend yield is N/A and the payout ratio is 0.0%, the company does not distribute dividends to shareholders, effectively meaning it reinvests any available resources or retains losses into the business rather than paying cash distributions. This absence of dividend payments aligns with the company's current financial profile of negative free cash flow and negative net income, where capital preservation is prioritized over income generation for existing shareholders. Consequently, the overall growth and income profile for Akanda Corp. is defined by high volatility, a lack of current income distribution, and a reliance on future operational improvements to transition from a cash-burning entity to a profitable one.